Despite small sample size, the prevalence of germline BRCA1/2 mutations was similar in Taiwan compared with Western countries in cases of ovarian cancer (26.1% in serous carcinoma) or breast cancer (11.1% in early‐onset, or familial breast cancer) 29, 30. This evidence concerns the gene BRCA1 and serous adenocarcinoma.